Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.18−0.43 (-2.44%)
Close on Nov 17, 2026Market cap $1.95BP/E –Yield –
Immunome price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Immunome's price to sales ratio was 373.9× on Apr 30, 2026, against 62.7× a year earlier. Over the last 2 years it ranged from 43.4× to 373.9×, with a median of 74.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 373.9× | +170.4 |
| 2025 | Dec 31, 2025 | 203.5× | +140.2 |
| 2024 | Dec 31, 2024 | 63.4× | – |
See a number that looks wrong?